Skip to main content

Table 1 Transplant outcomes of patients who underwent NFD or FD HAPLO

From: Similar outcomes following non-first-degree and first-degree related donor haploidentical hematopoietic cell transplantation for acute leukemia patients in complete remission: a study from the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

 

2 years

180 days

2 years

Relapse

NRM

LFS

OS

GRFS

Acute GVHD II-IV

Acute GVHD III-IV

Chronic GVHD

Ext. chronic GVHD

FD

22.6%

[17.8–27.7]

17.7%

[13.5–22.3]

59.7%

[53.7–65.3]

68.3%

[62.5–73.5]

47.8%

[41.8–53.6]

29.1%

[24–34.4]

9.1%

[6.2–12.7]

31%

[25.6–36.6]

9.9%

[6.6–13.9]

NFD

21.1%

[13.9–29.3]

13.2%

[7.7–20.2]

65.7%

[55.9–73.9]

71.8%

[62.3–79.4]

50.9%

[41–60]

24%

[16.8–31.9]

10.7%

[6–17]

38.9%

[29.4–48.3]

15.3%

[9.1–22.9]

HR (95% CI)

1.04 (0.69–1.58)

0.77 (0.45–1.31)

0.92 (0.66–1.27)

0.9 (0.63–1.28)

0.95 (0.72–1.25)

0.8 (0.52–1.23)

1.28 (0.68–2.4)

1.17 (0.81–1.69)

1.44 (0.82–2.52)

p value

0.84

0.33

0.6

0.56

0.69

0.31

0.44

0.41

0.2

  1. NRM, non-relapse mortality; LFS, leukemia-free survival; OS, overall survival; GRFS, GVHD-free, relapse-free survival; GVHD, graft-versus-host disease; Ext, extensive; FD, first-degree; NFD, non-first-degree; HR, hazard ratio